UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

 

(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 31, 2013

 

BioTelemetry, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

333-188058

 

46-2568498

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

227 Washington Street, #210

Conshohocken, PA

 

19428

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (610) 729-7000

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01                                           Other Events.

 

We are filing this Amendment No. 1 to the Current Report on Form 8-K for the sole purpose of effecting a technical correction to the EDGAR submission header used in the original Form 8-K filed on August 1, 2013.  The original filing, and this Amendment No. 1, will be superseded by a Form 8-K12g3 to be filed by BioTelemetry, Inc. on the date hereof (the “Subsequent Filing”).  The purpose of the Subsequent Filing is to reflect that BioTelemetry, Inc. is a successor issuer to CardioNet, Inc. pursuant to Rule 12g-3 as described in the original Form 8-K, and to obtain a Commission File Number for use in subsequent filings to be made by BioTelemetry, Inc. under the Securities Exchange Act of 1934, as amended.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BioTelemetry, Inc.

 

 

 

 

 

By:

/s/ Peter Ferola

 

 

Peter Ferola

 

 

Senior Vice President and General Counsel

Date: September 6, 2013

 

 

3